Related Experiment Video
Updated: Jul 1, 2025
07:05
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
Published on: November 9, 2016
23.0K
Botulinum Toxin A and B for Palmoplantar Hyperhidrosis.
Trond Eilertsen1, Bjørn Øivind Kvammen2,3, Øystein Grimstad2,3
1Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway. tre025@post.uit.no.
Dermatology and Therapy
|February 29, 2024
Summary
Botulinum toxin A (BTX-A) and botulinum toxin B (BTX-B) injections significantly improved quality of life for patients with palmoplantar hyperhidrosis. Excessive sweating was reduced, enhancing patient-reported outcomes.
Area of Science:
- Dermatology
- Neurology
- Quality of Life Research
Background:
- Hyperhidrosis is excessive sweating unrelated to temperature, negatively impacting quality of life.
- Palmoplantar hyperhidrosis affects the hands and feet, causing significant distress.
Purpose of the Study:
- To assess the effectiveness of botulinum toxin A (BTX-A) and botulinum toxin B (BTX-B) in treating palmoplantar hyperhidrosis.
- To evaluate the impact of these treatments on patient-reported quality of life outcomes.
Main Methods:
- 35 patients with palmar and/or plantar hyperhidrosis were treated with BTX-A or BTX-B.
- Specific dosages were administered to palms and soles, with precautions to avoid muscle weakness.
Main Results:
- A significant improvement in the Dermatology Life Quality Index (DLQI) was observed.
- Patient-reported outcomes showed a substantial enhancement in quality of life post-treatment.
Conclusions:
- BTX-A and BTX-B are effective treatments for palmoplantar hyperhidrosis.
- Treatment with botulinum toxins leads to a significant improvement in the quality of life for affected individuals.
More Related Videos
Related Concept Videos
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
680
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
680
01:31Skeletal Muscle Relaxants: Therapeutic Uses
482
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
482
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
420
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
420
01:19Depolarizing Blockers: Pharmocokinetics
325
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
325
01:28Depolarizing Blockers: Mechanism of Action
1.6K
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
1.6K
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
1.8K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.8K